Cargando…

Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study

Preclinical studies show that blocking Interleukin–1 (IL–1) retards the progression of Amyotrophic Lateral Sclerosis (ALS). We assessed the safety of Anakinra (ANA), an IL–1 receptor antagonist, in ALS patients. In a single arm pilot study we treated 17 ALS patients with ANA (100 mg) daily for one y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maier, André, Deigendesch, Nikolaus, Müller, Kathrin, Weishaupt, Jochen H., Krannich, Alexander, Röhle, Robert, Meissner, Felix, Molawi, Kaaweh, Münch, Christoph, Holm, Teresa, Meyer, Robert, Meyer, Thomas, Zychlinsky, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596620/ https://www.ncbi.nlm.nih.gov/pubmed/26444282 http://dx.doi.org/10.1371/journal.pone.0139684

Ejemplares similares

Severe Loss of Appetite in Amyotrophic Lateral Sclerosis Patients: Online Self-Assessment Study
por: Holm, Teresa, et al.
Publicado: (2013)

The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats
por: Vallejo, Susana, et al.
Publicado: (2014)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
por: Green, Elys A., et al.
Publicado: (2022)

Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
por: Meyer, Robert, et al.
Publicado: (2018)

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2021)

Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
por: Yamanaka, Gaku, et al.
Publicado: (2021)

The Anti-Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Apolipoprotein E Knockout Mice
por: Ku, Eu Jeong, et al.
Publicado: (2022)

Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis
por: Freischmidt, Axel, et al.
Publicado: (2013)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature
por: Mulders-Manders, Catharina M., et al.
Publicado: (2017)

PReS-FINAL-2333: Long term efficacy of interleukin-1 receptor antagonist (anakinra) in a multicentric cohort of patients affected by idiopathic recurrent pericarditis
por: Finetti, M, et al.
Publicado: (2013)

Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
por: Divithotawela, Chandima, et al.
Publicado: (2015)

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
por: Hübner, Max, et al.
Publicado: (2020)

Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect and decreases morphine tolerance development by modulating oxidative stress and endoplasmic reticulum stress in rats
por: AVCI, Onur, et al.
Publicado: (2020)

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review
por: Baskar, Shankar, et al.
Publicado: (2016)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
por: Meyer, Thomas, et al.
Publicado: (2019)

Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial
por: Maier, André, et al.
Publicado: (2012)

Post-infection immunocomplex glomerulonephritis and Legionnaires' disease in a patient with adult Still's disease during treatment with interleukin 1 receptor antagonist anakinra: a case report
por: Scholtze, Dieter, et al.
Publicado: (2011)

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
por: Quartier, Pierre, et al.
Publicado: (2010)

Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosis–Associated Motor Impairment: Observational Online Study
por: Maier, André, et al.
Publicado: (2021)

M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation
por: Kandalla, Prashanth K., et al.
Publicado: (2016)

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status
por: Bader, Jakob Maximilian, et al.
Publicado: (2022)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis
por: Volk, Alexander E., et al.
Publicado: (2018)

Memory-guided navigation in amyotrophic lateral sclerosis
por: Maier, Patrizia M., et al.
Publicado: (2023)

Modulation of Post-Traumatic Immune Response Using the IL-1 Receptor Antagonist Anakinra for Improved Visual Outcomes
por: Evans, Lucy P., et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Anakinra: Jaundice: case report
Publicado: (2021)

Continuous IV infusion of anakinra
por: Saunders, Brittney N., et al.
Publicado: (2023)

Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
por: Ottaviani, Sébastien, et al.
Publicado: (2013)

IL‐1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis
por: Gorelik, M., et al.
Publicado: (2019)

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety
por: Hong, Dongsheng, et al.
Publicado: (2014)

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
por: Del Buono, Marco Giuseppe, et al.
Publicado: (2022)

Refractory Sweet Syndrome Treated with Anakinra
por: Shahid, Zainab, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6o53c77r8deaiv0151h6irq045